Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Definium TherapeuticsDFTX +3.42%28 3-Year EPS without NRI Growth Rate is 5.00% as of Jun. 2026, which is at its 10-year median of 5.00. GuruFocus rates DFTX with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,162 Biotechnology companies, Definium Therapeutics ranks worse than 65.32% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 5.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 8.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Definium Therapeutics was 26.60% per year. The lowest was -6.00% per year. And the median was 5.00% per year.
Definium Therapeutics (NAS:DFTX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Definium Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
DFTX vs SRRK, DNTH, ORKA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Definium Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Definium Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Definium Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Definium Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Definium Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 5.00% mean?
Definium Therapeutics (DFTX) has a 3-Year EPS without NRI Growth Rate of 5.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Definium Therapeutics and its competitors. This is near median its historical median of 5.00. According to the industry distribution chart, Definium Therapeutics ranks #759 out of 1162 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Definium Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Definium Therapeutics' current 3-Year EPS without NRI Growth Rate of 5.00% is near median its 10-year median of 5.00. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Definium Therapeutics' value of 5.00% is 69.1% below this industry median. Based on the distribution chart, Definium Therapeutics ranks #759 out of 1162 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Definium Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' 3-Year EPS without NRI Growth Rate compare to SRRK and DNTH?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #759 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This places Definium Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Definium Therapeutics' value of 5.00% is 69.1% below this benchmark. While the company's 10-year median is 5.00 vs. the industry median of 16.20, Definium Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Definium Therapeutics's current 3-Year EPS without NRI Growth Rate of 5.00% is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Definium Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Definium Therapeutics's current 3-Year EPS without NRI Growth Rate is 5.00%, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current 3-Year EPS without NRI Growth Rate of 5.00%. The current 3-Year EPS without NRI Growth Rate is 5.00%, which is near median its 10-year median of 5.00 and 69.1% below the Biotechnology industry median of 16.20. Definium Therapeutics' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current 3-Year EPS without NRI Growth Rate is 5.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
28GF Score
Get the complete analysis for DFTX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DFTX has been successfully added to your 
